| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
(1) We have examined phosphorylated ubiquitin staining using sporadic autopsy Parkinson’s disease (PD) patients’ brains to assess the possibility of phosphorylated ubiquitin as a biomarker. If mitochondrial quality was low in sporadic PD patients’ brains, phosphorylated ubiquitin would accumulate at mitochondria. Small amount of phosphorylated ubiquitin signal was detected in healthy midbrain with increasing age. However, in PD midbrain, several types of phosphorylated ubiquitin signals were observed in a broad area and the amount of signal was larger than that of healthy control. This strategy may be a useful diagnostic approach for impaired mitochondria-derived phosphorylated ubiquitin accumulation.
(2) POLGA-mutated PARKIN knockout mice are subjected to behavioral and pathological analysis to assess PD-like phenotype. We are now evaluating whether each mouse group shows decline in motor coordination function and the number of dopaminergic neuron with age.
|
